Skip to content

Ocular Therapeutix

US · OCUL #2978 by market cap Listed 1970
5.57 -0.29 -4.95%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 5.76 -1.71%
After-hours 5.60 +0.54%
11.735.575.572026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on OCUL?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -51.1% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 13.2% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days E → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 87.3% Better than 95%
Operating margin -519.8% Better than 4%
Net margin -511.9% Better than 3%
Return on equity -54.9% Better than 9%
Return on invested capital -48.5% Better than 6%
Momentum D-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -49.7% Better than 6%
6-month return -32.3% Better than 16%
12-month return (ex latest month) -46.9% Better than 4%
Distance below 52-week high 66.1% Better than 8%
Financial Health B+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 15.4x Better than 97%
Debt to assets 9.5% Better than 71%
Interest coverage -21.5x Better than 10%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 351.3% Better than 98%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -10.31%
1M -16.24%
3M -49.77%
6M -30.64%
YTD -54.12%
1Y -52.47%
3Y +137.02%
5Y -16.74%

Key statistics

Price & volume

Prev close
5.86
Open
5.76
Day range
5.54 - 5.95
Avg price
5.66
Volume
2.90M
Turnover
16.38M
Amplitude
7.00%
52-week range
5.54 - 16.44

Valuation

P/E
-3.92
P/E (TTM)
-3.87
P/B
2.78
EPS
-1.42
Net profit
-312.43M
Net assets
440.93M

Share structure

Market cap
1.23B
Float cap
1.02B
Shares out
220.02M
Float shares
182.98M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 0% of range
5.54 16.44

66.1% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-361.59K net over the window

Short interest

Shares short
29.00M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Ocular Therapeutix (OCUL)?

Ocular Therapeutix last traded at 5.57. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Ocular Therapeutix's market cap?

About 1.23B.

What is the P/E ratio of Ocular Therapeutix?

The trailing twelve-month P/E is -3.87. The Valuation tab shows it against the stock's own five-year range.

Does Ocular Therapeutix pay a dividend?

Ocular Therapeutix does not currently pay a regular dividend.

Is Ocular Therapeutix a buy according to analysts?

The consensus of 8 analysts is a Buy rating, with an average 12-month price target of 25.14, which implies 351.3% upside from the current price. This is not investment advice.

What is Ocular Therapeutix's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Ocular Therapeutix a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Ocular Therapeutix discussion 0 comments

Add a comment